CWG
NDRM

C WorldWide Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

C WorldWide Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-92,800
Closed -$2.77M – 135
2017
Q2 		$2.77M Buy
+92,800
New +$2.4M 0.04% 82

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

C WorldWide Group's NDRM Position: Q3 2017 in Review

C WorldWide Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 92,800 shares — an estimated $2.77M sold.

C WorldWide Group first reported a position in NDRM in Q2 2017 and held it in 1 quarter. The position peaked at $2.77M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • C WorldWide Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • C WorldWide Group sold 92,800 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $2.77M.
  • C WorldWide Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2017 and held it in 1 quarter.
  • C WorldWide Group's NeuroDerm Ltd. Ordinary Shares position peaked at $2.77M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on C WorldWide Group's 13F filing for Q3 2017, filed 6 Nov 2017.